NCT01757288View on ClinicalTrials.gov

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

March 25, 2013

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Interventions
DRUG

NAB-PACLITAXEL

nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks

DRUG

PACLITAXEL

DRUG

NAB-PACLITAXEL

nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks

Trial Locations (5)

14642

University of Rochester, Rochester

15232

UPMC Cancer Center, Pittsburgh

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt-Ingram Cancer Center, Nashville

75239

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER